One case reported that the use of interleukin-17A (IL-17A) inhibitor (Secukinumab) can effectively control patients with critical illness.[15] In the management of ICI-DM, the impairment of islet function by ICIs is irreversible, so patients can only be treated with insulin hypoglycemia. This evidence concerns the gene INS and diabetes mellitus.